跳至主要内容
临床试验/NCT07031882
NCT07031882暂停不适用

Liberty Analyzer WBC System: Reference Interval Study

Entia Ltd1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2026年3月19日最近更新:
干预措施

试验速览

阶段
不适用
状态
暂停
发起方
Entia Ltd
入组人数
300
试验地点
1
主要终点
To establish the 95% reference interval for WBC for the Liberty Analyzer WBC System, reported with 90% confidence intervals.

研究概览

简要总结

The purpose of this study is to establish the reference intervals for WBC and granulocytes for the Liberty Analyzer WBC System.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥21 years old at the time of study entry
  • Able to provide written informed consent

排除标准

  • Inadequate use and understanding of the English language, requiring a translator
  • Undergone tattooing or body piercing within the 7 days prior to the study visit
  • Undergone vaccination within the 7 days prior to the study visit
  • Episode of upper respiratory infection within the 30 days prior to the study visit
  • Use of oral corticosteroid medications within the 30 days prior to the study visit
  • Undergone surgery within the 90 days prior to the study visit
  • Been hospitalised within the 90 days prior to the study visit
  • Donated blood or plasma within the 90 days prior to the study visit
  • Pregnant at the time of the study visit
  • Breastfeeding at the time of the study visit
  • Current diagnosis of anemia (including iron deficiency anemia, vitamin deficiency anemia, aplastic anemia and/or hemolytic anemia)
  • Current diagnosis of high blood pressure
  • Current diagnosis of diabetes mellitus
  • History or current diagnosis of chronic kidney disease or end-stage renal disease
  • History or current diagnosis of cancer
  • History or current diagnosis of cardiovascular disease
  • History or current use of radiotherapy of the chest or abdomen
  • History or current diagnosis of the following conditions known to affect the CBC differential count:
  • Immune Thrombocytopenic Purpura (ITP)
  • Systemic Lupus Erythematosus (SLE)
  • Rheumatoid Arthritis (RA)
  • Antiphospholipid Syndrome (APS)
  • Sjogren's Syndrome
  • Tuberculosis (TB)
  • Hepatitis B/C
  • G6PD Deficiency
  • Sickle Cell Disease/Trait
  • Inflammatory Bowel Disease (IBD)
  • Eptein Barr virus
  • CMV Cytomegalovirus
  • Myelodysplastic Syndromes (MDS) / CMML
  • Participants who meet the following criteria will be excluded a posteriori:
  • Hemoglobin, hematocrit, red cell and/or total white blood cell count obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
  • Iron, ferritin, transferrin, total Iron Binding Capacity (TIBC) and/or transferrin saturation results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
  • Alanine aminotransferase (ALT), aspartate aminotransferase ( AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, conjugated bilirubin, albumin and/or total protein results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
  • Creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), sodium, potassium, chloride and/or bicarbonate results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
  • C-reactive protein (CRP) results obtained by standard laboratory analysis of the participant's venous blood sample, that fall outside of the applicable reference interval in use at the study site.
  • Self-report to be taking medication(s) that are subsequently identified as interfering substances for the Liberty Analyzer WBC System

研究组 & 干预措施

Healthy volunteers

干预措施: Liberty Analyzer WBC System (Device)

结局指标

主要结局

To establish the 95% reference interval for WBC for the Liberty Analyzer WBC System, reported with 90% confidence intervals.

时间窗: Through study completion, an average of 1 day

To establish the 95% reference interval for absolute granulocytes for the Liberty Analyzer WBC System, reported with 90% confidence intervals.

时间窗: Through study completion, an average of 1 day

次要结局

未报告次要终点

研究者

发起方
Entia Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验